270 related articles for article (PubMed ID: 32257152)
1. Predictors of Epstein-Barr virus serostatus and implications for vaccine policy: A systematic review of the literature.
Winter JR; Jackson C; Lewis JE; Taylor GS; Thomas OG; Stagg HR
J Glob Health; 2020 Jun; 10(1):010404. PubMed ID: 32257152
[TBL] [Abstract][Full Text] [Related]
2. Vaccine Development for Epstein-Barr Virus.
Cohen JI
Adv Exp Med Biol; 2018; 1045():477-493. PubMed ID: 29896681
[TBL] [Abstract][Full Text] [Related]
3. Predictors of Epstein-Barr virus serostatus in young people in England.
Winter JR; Taylor GS; Thomas OG; Jackson C; Lewis JEA; Stagg HR
BMC Infect Dis; 2019 Nov; 19(1):1007. PubMed ID: 31779585
[TBL] [Abstract][Full Text] [Related]
4. The Development of Prophylactic and Therapeutic EBV Vaccines.
Smith C; Khanna R
Curr Top Microbiol Immunol; 2015; 391():455-73. PubMed ID: 26428385
[TBL] [Abstract][Full Text] [Related]
5. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults.
Sokal EM; Hoppenbrouwers K; Vandermeulen C; Moutschen M; Léonard P; Moreels A; Haumont M; Bollen A; Smets F; Denis M
J Infect Dis; 2007 Dec; 196(12):1749-53. PubMed ID: 18190254
[TBL] [Abstract][Full Text] [Related]
6. Progress, prospects, and problems in Epstein-Barr virus vaccine development.
Balfour HH
Curr Opin Virol; 2014 Jun; 6():1-5. PubMed ID: 24632197
[TBL] [Abstract][Full Text] [Related]
7. The promise of a prophylactic Epstein-Barr virus vaccine.
Balfour HH; Schmeling DO; Grimm-Geris JM
Pediatr Res; 2020 Jan; 87(2):345-352. PubMed ID: 31641280
[TBL] [Abstract][Full Text] [Related]
8. Infectious mononucleosis and Epstein-Barr virus.
Vetsika EK; Callan M
Expert Rev Mol Med; 2004 Nov; 6(23):1-16. PubMed ID: 15541197
[TBL] [Abstract][Full Text] [Related]
9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
10. Modelling the dynamics of EBV transmission to inform a vaccine target product profile and future vaccination strategy.
Goscé L; Winter JR; Taylor GS; Lewis JEA; Stagg HR
Sci Rep; 2019 Jun; 9(1):9290. PubMed ID: 31243321
[TBL] [Abstract][Full Text] [Related]
11. Vaccination against the Epstein-Barr virus.
Rühl J; Leung CS; Münz C
Cell Mol Life Sci; 2020 Nov; 77(21):4315-4324. PubMed ID: 32367191
[TBL] [Abstract][Full Text] [Related]
12. Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases.
Cui X; Snapper CM
Front Immunol; 2021; 12():734471. PubMed ID: 34691042
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for Epstein Barr virus-associated cancers: a systematic review, critical appraisal, and mapping of the epidemiological evidence.
Bakkalci D; Jia Y; Winter JR; Lewis JE; Taylor GS; Stagg HR
J Glob Health; 2020 Jun; 10(1):010405. PubMed ID: 32257153
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology of Epstein-Barr virus infection and infectious mononucleosis in the United Kingdom.
Kuri A; Jacobs BM; Vickaryous N; Pakpoor J; Middeldorp J; Giovannoni G; Dobson R
BMC Public Health; 2020 Jun; 20(1):912. PubMed ID: 32532296
[TBL] [Abstract][Full Text] [Related]
15. Infectious Mononucleosis.
Dunmire SK; Hogquist KA; Balfour HH
Curr Top Microbiol Immunol; 2015; 390(Pt 1):211-40. PubMed ID: 26424648
[TBL] [Abstract][Full Text] [Related]
16. The potential of currently unavailable herpes virus vaccines.
Rajčáni J; Bánáti F; Szenthe K; Szathmary S
Expert Rev Vaccines; 2018 Mar; 17(3):239-248. PubMed ID: 29313728
[TBL] [Abstract][Full Text] [Related]
17. On the aetiology of Hodgkin lymphoma.
Hjalgrim H
Dan Med J; 2012 Jul; 59(7):B4485. PubMed ID: 22759852
[TBL] [Abstract][Full Text] [Related]
18. Murine gamma-herpesvirus 68 glycoprotein 150 protects against virus-induced mononucleosis: a model system for gamma-herpesvirus vaccination.
Stewart JP; Micali N; Usherwood EJ; Bonina L; Nash AA
Vaccine; 1999 Jan; 17(2):152-7. PubMed ID: 9987149
[TBL] [Abstract][Full Text] [Related]
19. Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation.
Khanna R; Moss DJ; Burrows SR
Immunol Rev; 1999 Aug; 170():49-64. PubMed ID: 10566141
[TBL] [Abstract][Full Text] [Related]
20. Regulatory T cell activity in primary and persistent Epstein-Barr virus infection.
Wingate PJ; McAulay KA; Anthony IC; Crawford DH
J Med Virol; 2009 May; 81(5):870-7. PubMed ID: 19319950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
